Science Daily -
2 Apr 2018 20:24
Investigators have found that combined treatment with two cancer immunotherapy drugs -- one a novel immune modulator and one that focuses and activates the anti-tumor immune response -- significantly prolonged survival in mouse models of the aggressive cancer malignant mesothelioma.
Share this Article